The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study

Cardiopulmonary Bypass Clinical Trial

Official title:

The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05300802
• Other study ID #: LB.02.01/VII/581/KEP058/2021
• Secondary ID: LB.02.01/VII/581
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: December 16, 2021
• Est. completion date: July 16, 2022

Study information

• Verified date: September 2022
• Source: National Cardiovascular Center Harapan Kita Hospital Indonesia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Congenital Heart Diseases (CHD) are one of the most common congenital anomalies. Worldwide, 8 to 9 out of 1000 of children are born with a CHD, of which 25 percent of are cyanotic CHD. In Indonesia, the prevalence is 43.200 out of 4.8 million births annually. The morbidity and mortality of cyanotic CHDs in the National Cardiovascular Center Harapan Kita (NCCHK) are higher than acyanotic CHDs. Open-heart surgery using a cardiopulmonary bypass (CPB) machine temporarily takes over the function of the heart and lung during surgery. However, the use of CPB has several negative effects such myocardial injury, systemic inflammation, and reperfusion injury. Preoperative hypoxia in cyanotic CHD tends to be associated with a higher risk of myocardial injury. Myocardial protection has an important role in attenuating those effects. Generally, we use a cardioplegia solution as myocardial protection, but there are several non-cardioplegia techniques that can be used to enhance myocardial protection during cardiac bypass, such as adding an anesthetic agent. Dexmedetomidine (DEX) is the active dextroisomer of medetomidine, a selective α-2 adrenergic, which has major effects including hypnosis, sedation, and analgesia as well as cardiovascular effects. The sedation is induced by stimulating the α-2 adrenergic receptor in the locus coeruleus (LC) in the pons cerebri. DEX also increases the level of GABA and Galanin and reduces endogenous norepinephrine. The lower level of endogenous norepinephrine decreases the afterload of the ventricles, increases cardiac output, and reduces myocardial injury as a result. Furthermore, the peripheral effects of DEX can reduce myocardial ischemia-reperfusion (MIR) by inhibiting NF-кB pathway activation and reducing the number of proinflammatory cytokines released. Research related to the priming and infusion of DEX during CPB in patients with cyanotic CHDs who are undergoing open-heart surgery is less reported. The aims of this study are to determine the effectiveness of the priming and infusion of DEX during CPB as myocardial protection by using two different doses compared to the control group. The population included in this study is pediatric patients with cyanotic CHD who are undergoing open-heart surgery using CPB and who classified as 6 to 9 in the Aristotle Score.

Description:

The investigators will conduct a double-blind randomized controlled trial preliminary study to determine the effectiveness of the priming and infusion of DEX during CPB as myocardial protection by using two different doses compared to the control group. The population included in this study will be pediatric patients with cyanotic CHD who are undergoing open-heart surgery using CPB and who classified as 6 to 9 in the Aristotle Score. This study was approved by the research ethical committee (Institutional Review Board) of the National Cardiovascular Center Harapan Kita Jakarta (NCCHK). Before randomization, participants who are eligible based on inclusion and exclusion criterias will be given informed consent. If the guardians of the patients agree, the patient will be included in this research. Fifteen pediatric patients with cyanotic CHD will be randomly divided into three groups A, B, and C. Group A is the control group and will be given 50 ml Ringer acetate solution in a 50 ml syringe that will be added to the priming solution in CPB, followed by 50 ml of Ringer acetate solution administered in a syringe pump infusion running at 25 ml/hour and which will be ended by the end of CPB. Group B will received DEX 1 mcg/kg diluted in 50 ml of Ringer acetate solution in a 50 ml syringe added in the priming solution in CPB, followed by 50 ml of Ringer acetate solution administered in a syringe pump infusion running at 25 ml/hour and which will be ended by the end of CPB. Group C will be administered 0.5 mcg/kg DEX, diluted in 50 ml of Ringer acetate solution in a 50 ml syringe added in the priming solution in CPB, followed by 0.25 mcg/kg/hour DEX diluted in 50 ml of Ringer acetate solution administered in a syringe pump infusion running at 25 ml/hour infusion which will be ended by the end of CPB.

Age, gender, body weight, body length, body surface area, Aristotle scores, aortic cross-clamp time, CPB time, and operation time are included as demographics and characteristics data. The investigators will measure myocardial injury biomarker serum levels (Troponin I) and cytokines proinflammatory biomarker serum levels (IL-6) as the primary outcome of myocardial protection. Serum levels of troponin I and IL-6 will be taken 4 times (T1: 5 minutes after induction as baseline level; T2: 1 hour after CPB; T3: 6 hours after CPB, and T4: 24 hours after CPB). Secondary outcomes include hemodynamic profile (Cardiac output, cardiac index, and systemic vascular resistance, at 6 hours, 24 hours, and 48 hours after CPB plus serum lactate levels at 5 minutes after induction as baseline level, 1 hour, 6 hours, and 24 hours after CPB), morbidity outcomes (the highest Vasoinotropic Score at the first 24 hours after CPB, length of mechanical ventilation, and length of intensive care stay), and adverse event occurrences such as hypotension and bradycardia (at 5 minutes after induction as baseline level, 1 hour, 6 hours, and 24 hours after CPB).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 16, 2022
• Est. primary completion date: May 16, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 6 Years

Eligibility

Inclusion Criteria:

• All the patients guardian consent to participate in this study

• Patient with Cyanotic CHD who are undergoing open-heart surgery using CPB with an Aristotle score of 6-9

• Patient is aged between 1 month to 6 years

Exclusion Criteria:

• Elective surgery patients who change into an emergency case surgery

• Patient with procalcitonin levels exceeding 0.5 ng/ml with the symptoms of infection

• Patient with liver dysfunction as measured by an increase of Glutamic Oxaloacetic Transaminase (SGOT)/ Serum Glutamic Pyruvic Transaminase (SGPT) levels more than 1.5 times from baseline

• Patient with Renal dysfunction as measured by creatinine levels exceeding 2 mg/dL

Drop out Criteria:

• Duration of CPB and/or Aortic cross-clamp time exceeding 120 minutes

• Intraoperative anatomy of CHDs finding is different from the preoperative diagnosis so that the patient no longer fulfils the Aristotle score of 6-9

• Surgery requires more than two attempts of CPB

• Patient fails to wean from CPB

• Patient requires ECMO (Extracorporeal Membrane Oxygenator) postoperatively

• Patient dies on the operating table

Related Conditions & MeSH terms

• Cardiopulmonary Bypass
• Congenital Heart Disease in Children
• Heart Defects, Congenital
• Heart Diseases

Intervention

Drug:
• Placebo
50 ml of Ringer acetate will be added to the priming solution and followed by a continuous 50 ml infusion of Ringer acetate running at 25 ml/hour.
• Dexmedetomidine Hcl 100 Mcg/mL Inj
1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
• Dexmedetomidine Hcl 100 Mcg/mL Inj
0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.

Locations

Country	Name	City	State
Indonesia	National Cardiovascular Center Harapan Kita Hospital Indonesia	Jakarta

Sponsors (1)

Lead Sponsor	Collaborator
National Cardiovascular Center Harapan Kita Hospital Indonesia

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum Troponin I at baseline	Troponin I serum concentration will be measured using RnD Quantikine reagent (ng/mL)	5 minutes after induction of anesthesia (T1)
Primary	Serum Troponin I at 1 hour after cardiopulmonary bypass	Troponin I serum concentration will be measured using RnD Quantikine reagent (ng/mL)	1 hour after cardiopulmonary bypass (T2)
Primary	Serum Troponin I at 6 hours after cardiopulmonary bypass	Troponin I serum concentration will be measured using RnD Quantikine reagent (ng/mL)	6 hours after cardiopulmonary bypass (T3)
Primary	Serum Troponin I at 24 hours after cardiopulmonary bypass	Troponin I serum concentration will be measured using RnD Quantikine reagent (ng/mL)	24 hours after cardiopulmonary bypass (T4)
Primary	Serum IL-6 at baseline	IL-6 serum concentration will measured using an Elecsys IL-6 reagent (pg/mL)	5 minutes after induction of anesthesia (T1)
Primary	Serum IL-6 at 1 hour after cardiopulmonary bypass	IL-6 serum concentration will measured using an Elecsys IL-6 reagent (pg/mL)	1 hour after cardiopulmonary bypass (T2)
Primary	Serum IL-6 at 6 hours after cardiopulmonary bypass	IL-6 serum concentration will measured using an Elecsys IL-6 reagent (pg/mL)	6 hours after cardiopulmonary bypass (T3)
Primary	Serum IL-6 at 24 hours after cardiopulmonary bypass	IL-6 serum concentration will measured using an Elecsys IL-6 reagent (pg/mL)	24 hours after cardiopulmonary bypass (T4)
Secondary	Cardiac output	Cardiac output will be measured using transthoracic echocardiography (L/min)	6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass
Secondary	Cardiac Index	Cardiac index will be measured using transthoracic echocardiography (L/min)	6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass
Secondary	Systemic Vascular Resistance (SVR)	SVR will be measured using transthoracic echocardiography (L/min)	6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass
Secondary	Serum Lactate	Serum lactate will be measured using an enzymatic method with a blood gas analyzer machine (mmol/L)	5 minutes after anesthesia induction (T1), and then 1 hour (T2), 6 hours (T3), and 24 hours (T4) after cardiopulmonary bypass
Secondary	VIS Score	Vasoinotropic score will be measured using the VIS formula	6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass
Secondary	Mechanical ventilation time	Mechanical ventilation time will be measured from the moment the patient arrives at the intensive care unit until the patient is extubated	3 days (or until the patient is extubated)
Secondary	Hospital length of stay in the intensive care unit	Hospital length of stay in the intensive care unit will be measured from the moment the patient is admitted to the intensive care unit after the surgery until discharge from intensive care unit	7 days (or until the patient is discharge from intensive care unit)
Secondary	Adverse effects of DEX related to the hemodynamic profile ( hypotension and bradycardia)	Adverse effects of DEX related to the hemodynamic profile ( hypotension and bradycardia)	5 minutes after anesthesia induction (T1), and then 1 hour (T2), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass